The company has agreed to pay $2.2 billion to settle around 80,000 state court product liability cases alleging injury from Zantac (ranitidine), most of which had been consolidated in a Delaware ...

Zantac Litigation is Born “The best starting point involves a private company known as Valisure. Valisure theorized that ranitidine [aka Zantac] has the potential to degrade into a carcinogen known as ...

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...

Class action and personal injury lawsuits have been filed in US courts after the Food and Drug Administration warned in 2019 that some ranitidine drugs including Zantac contained low levels of an ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

(RTTNews) - GSK plc (GSK, GSK.L) announced that it has reached agreements with 10 plaintiff firms representing approximately 93% (around 80,000) of the Zantac (ranitidine) product liability cases ...

These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company. Under these agreements, GSK will pay up to $2.2 billion to resolve the claims, contingent ...

The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer ...